Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 16, 2022 · Filed March 18, 2022
Section 16 reporting ended · disclosed 2022-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,343 |
Ending reported balance
After 2022-03-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-16 · Exercise / conversion · Acquired 6,000 · Balance 25,845 F1: This reflects the number of restricted stock units that became vested as of March 16, 2022. Row 2 · 2022-03-16 · Tax withholding · Disposed 1,502 · Balance 24,343 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,000 |
Reported balance
After 2022-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-16 · Exercise / conversion · Disposed 6,000 · Balance 6,000 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,829 |
Reported balance
After 2022-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-16 · Grant · Acquired 35,829 · Balance 35,829 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2032-03-16 | Direct | 33,419 |
Reported balance
After 2022-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-16 · Grant · Acquired 33,419 · Balance 33,419 F6: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2022.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 4,375 | $4.81 | $21,043.75 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 5 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,313 | $3.67 | $19,498.71 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 4 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,250 | $5.45 | $6,812.50 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 5,480 | $20.00 | $109,600.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,185 F1 · shares: This Form is being filed in part to report the exercise of a stock option for a total of 40,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 34,520 shares of common stock. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 40,000 | $2.74 | $109,600.00 |
DisclosureSEC source: 0001179110-17-013454 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed in part to report the exercise of a stock option for a total of 40,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 34,520 shares of common stock. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:43 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 25,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000079 · edgar.xml · derivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020(4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.